What is SOPH's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.62B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SOPH?

P/E (TTM) is n/a and 52-week range is $3.75 to $8.98 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SOPH figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SOPH?

The company profile lists revenue (TTM) near $99M, net income (TTM) near -$9.32B, EPS (TTM) near -$1.15 when available from the market-data feed. Figures are informational and may lag live markets.

Where is SOPHiA GENETICS SA based, and what identifiers does Chartloom list?

The company context section lists headquarters in Rolle, Vaud, CH, 85.1M shares outstanding, ISIN CH1125843347 when available from company profile and filing metadata.

SOPHiA GENETICS SA

$SOPH

Health Care · Health Care Technology

IR Run Scenarios

Browse other companiesFree AI scores and summaries for more stocks

SOPHiA GENETICS SA

$SOPH

Health Care · Health Care Technology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. The company is headquartered in Rolle, Vaud and currently employs 415 full-time employees. The company went IPO on 2021-07-23. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The firm has offices in Switzerland, France, and the United States and operates worldwide.

Employees

415

Website

www.sophiagenetics.com/

IPO

2021-07-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

CH1125843347

Headquarters

Rolle, Vaud, CH

Shares outstanding

85.1M

NAICS sector

Information

Institutional ownership

50.60%

Browse other companiesFree AI scores and summaries for more stocks

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. The company is headquartered in Rolle, Vaud and currently employs 415 full-time employees. The company went IPO on 2021-07-23. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The firm has offices in Switzerland, France, and the United States and operates worldwide.

Employees

415

Website

www.sophiagenetics.com/

IPO

2021-07-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

CH1125843347

Headquarters

Rolle, Vaud, CH

Shares outstanding

85.1M

NAICS sector

Information

Institutional ownership

50.60%